Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint
Los Angeles, December 9, 2021 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide […]